UBC PiMS Research Group
Pharmacoepidemiology in Multiple Sclerosis Research Group

Elaine Kingwell

Elaine Kingwell

Role:  Research Associate / Epidemiologist

Previous Academic Training: PhD in Epidemiology (UBC), MSc in Behavioural Neuroscience (University of Calgary), BSc (Hons) in Zoology and Psychology (University of Wales, Swansea)

Research interests and current projects include the epidemiology of MS; co-morbidities and mortality in MS; the natural course of MS and the long-term influence of MS disease-modifying therapies, with an emphasis on utilizing administrative and clinical databases for MS research. Funded through grants or awards from the MS Society of Canada, the Michael Smith Foundation for Health Research, the Canadian Institutes of Health Research, the National MS Society (U.S.) and the Fondation ARSEP (France).

Email: elainejk@mail.ubc.ca

 

Awards Received:

  • Michael Smith Foundation for Heath Research Postdoctoral Fellowship
  • Multiple Sclerosis Society of Canada Postdoctoral Fellowship
  • Canadian Institutes of Health Research Doctoral Research Award
  • Michael Smith Foundation for Health Research Doctoral Trainee Award
  • Alberta Heritage Foundation for Medical Research Studentship.

Publications:

  • Kingwell E, Zhu F, Marrie RA, Fisk JD, Wolfson C, Warren S, Profetto-McGrath J, Svenson LW, Jette N, Bhan V, Yu BN, Elliott L, Tremlett H. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). J Neurol. 2015; DOI: 10.1007/s00415-015-7842-0 [epub:24 Jul 2015].
  • Shirani A, Zhao Y, Petkau J, Gustafson P, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H. Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment. Biomed Res Int. 2015;2015:451912.
  • Zhang T, Shirani A, Zhao Y, Karim ME, Gustafson P, Petkau J, Evans C, Kingwell E, van der Kop ML, Zhu F, Oger J, Tremlett H. Beta-interferon exposure and onset of secondary progressive multiple sclerosis. Eur J Neurol. 2015;22(6):990-1000.
  • Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell TL, Wadelius M, Carleton B, Tremlett H. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin Drug Saf. 2014:1-13.
  • Karim ME, Gustafson P, Petkau J, Zhao Y, Shirani A, Kingwell E, Evans C, van der Kop M, Oger J, Tremlett H. Marginal Structural Cox Models for Estimating the Association Between beta-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort. Am J Epidemiol. 2014;180(2):160-71.
  • Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, Gustafson P, Zhao Y, Oger J, Tremlett H. Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiol Drug Saf. 2014;23(11):1213-22.
  • Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. Eur J Neurol. 2014;21(6):835-44.
  • Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H. Assessment of cancer risk with beta-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85(10):1096-1102.
  • Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N, Morrow SA, Fisk JD, Evans C, Beland SG, Kulaga S, Dykeman J, Wolfson C, Koch MW, Marrie RA. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13(1): 128.
  • Makhani N, Morrow SA, Fisk JD, Evans C, Beland SG, Kulaga S, Kingwell E, Marriot JJ, Dykeman J, Jette N, Pringsheim T, Wolfson C, Marrie RA, Koch MW.  MS incidence and prevalence in Africa, Asia, Australia and New Zealand: a systematic review. Mult Scler Relat Disord 2014;3(1):48-60.
  • Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol 2013;1;70(5):651-3.
  • Evans C, Beland S, Kulaga S, Wolfson C, Kingwell E, Marriot J, Koch M, Makhani N, Morrow S, Fisk J, Dykeman J, Jetté N, Pringsheim T, Marrie RA. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 2013;40:195-210.
  • Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012 Jul 18;308(3):247-56.
  • Kingwell E, Bajdik C, Phillips, Zhu F, Oger J, Hashimoto S, Tremlett H. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 2012;135:2973-9.
  • Langsetmo L, Hitchcock CL, Kingwell EJ, Davison KS, Berger C, Forsmo S, Zhou W, Kreiger N, Prior JC. Physical activity, body mass index and bone mineral density-associations in a prospective population-based cohort of women and men: The Canadian Multicentre Osteoporosis Study (CaMos). Bone. 2012; 50(1): 401-8.
  • Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu, F, Oger J, Tremlett H. Relative mortality and survival in multiple sclerosis: Findings from British Columbia, Canada. J. Neurol. Neurosurg Psychiatry 2012;83(1):61-6.
  • Evans C, Kingwell E, Zhu F, Oger J, Zhao Y, Tremlett H. Hospital admissions and multiple sclerosis: a retrospective, observational study examining temporal trends in a Canadian cohort. Am J Manag Care 2012;18(11):735-42.
  • Evans C, Tam J, Kingwell E, Oger J, Tremlett H. Long-term persistence with the immunomodulatory drugs for multiple sclerosis. Clin Ther 2012;34:341-50.
  • Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler 2011;18:442-50.
  • Chan S, Kingwell E, Oger J, Yoshida E, Tremlett H. High-dose beta-interferons increase the risk of hepatocellular liver injury in multiple sclerosis: A retrospective study. Mult Scler 2011; 17(3): 361-367.
  • Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010; 74(22): 1822-1826.
  • Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of secondary progressive MS. J. Neurol Neurosurg Psychiatry 2010;81:1039-1043.
  • Kingwell E, Prior JC, Ratner PA, Kennedy SM.  Direct-to-Participant Feedback and Awareness of Bone Mineral Density Testing Results in a Population-Based Sample of Mid-Aged Canadians. Osteoporosis Int 2010;21:307-319.
  • Koch M, Zhao Y, Yee I, Guimond C, Kingwell E, Rieckmann P, Sadovnick D, Tremlett H. Disease onset in familial and sporadic primary progressive multiple sclerosis. Mult Scler 2010;16(6):694-700.
  • Kingwell E, Leung A, Roger E, Duquette P, Rieckmann P, Tremlett H. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci 2010;292:57-62.
  • Kingwell E, Tremlett H. Interferons and Multiple Sclerosis: Is it plausible that beta-interferon treatment could influence the risk of cancer among MS patients? Expert Rev Neurother 2009;9(6):1263-5.
  • Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive MS. Neurology 2009;73(23):1996-2002.

a place of mind, The University of British Columbia

Pharmacoepidemiology in MS (PiMS)
2211 Wesbrook Mall,
Vancouver, BC, V6T 2B5, Canada
Email:

Emergency Procedures | Accessibility | Contact UBC  | © Copyright The University of British Columbia